Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Miles Sparrow FRACP, DMedSc

Miles P. Sparrow FRACP, DMedSc

Head, IBD Unit, The Alfred Hospital; Adjunct Clinical Associate Professor, Monash University, Melbourne, Australia

Associate Professor Miles Sparrow is a gastroenterologist specialising in inflammatory bowel disease (IBD) who is the Head of the IBD Unit at The Alfred Hospital, Melbourne and Adjunct Clinical Associate Professor at Monash University. His research interests include use and optimisation of immunomodulators, therapeutic drug monitoring and clinical trials of novel experimental agents in IBD. He is a member of the ANZIBD Consortium, GESA IBD Faculty,  BRIDGe and spECTRUM IBD special interest groups, and is a faculty member of the Cornerstones IBD medical education program. 

Disclosures

Miles Sparrow has received educational grants or research support from Gilead and Celltrion, speakers fees from Janssen, Abbvie, Ferring, Takeda, Pfizer, Shire, Celltrion, Eli-Lilly and Dr. Falk Pharma, and has served on advisory boards or received consultancy fees from Janssen, Takeda, Pfizer, Celgene, Abbvie, MSD, Emerge Health, Gilead, BMS, Celltrion and Eli-Lilly.